Summary: Rasagiline is a novel, investigational propargylamine that irreversibly and selectively inhibits monoamine oxidase type ... and irreversible inhibitor of MAO-B that has demonstrated ...

Am J Health Syst Pharm. 2006;63(10):915-928. Results of this study suggest that adjunctive rasagiline significantly reduces off time with efficacy similar to that observed by adding entacapone to ...

Tobacco and coffee contain bioactive compounds that may reduce Parkinson's disease risk by targeting key pathways such as MAO ...

For people with early Parkinson's, drug treatments such as levodopa, other dopamine agonists and monoamine oxidase B inhibitors may be considered. In the later stages, other drugs may be used with ...

is a new reversible selective monoamine oxidase B (MAO-B) inhibitor being studied for its potential in treating neurodegenerative diseases like Alzh The ongoing obesity Phase 2 trial is a ...

For people with early Parkinson's, drug treatments such as levodopa, other dopamine agonists and monoamine oxidase B inhibitors may be considered. In the later stages, other drugs may be used with ...

If you’ve been diagnosed with clinical depression, also known as major depressive disorder (MDD), rest assured there are many treatment options available. Some people will experience only one ...

Monoamine oxidase inhibitors (MAOIs) were the first antidepressants discovered in the 1950s ... 2018;32(5):865-891. doi:10.1002/ptr.6033 Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in ...

The participants were on stable levodopa or monoamine oxidase-B inhibitor monotherapy for more than three months before enrollment. Study participants received prasinezumab or placebo every 4 weeks ...

This production improves thrombin generation and clot formation in patients with hemophilia A or B with inhibitors. The approval is supported by data from the multicenter, open-label phase 3 ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson's ...